Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences, Inc. (TYRA) Healthcare & Pipeline Overview

Tyra Biosciences is a preclinical-stage biopharmaceutical company focused on developing precision oncology therapies. Their SNAP platform enables rapid drug design, targeting receptor tyrosine kinases (RTKs) like FGFRs to overcome tumor resistance. The lead candidate, TYRA-300, addresses FGFR3-altered bladder cancer, positioning Tyra in the competitive oncology market.

What Is the Investment Thesis for TYRA?

Tyra Biosciences presents a notable research candidate due to its innovative SNAP platform and promising pipeline of targeted cancer therapies. The company's lead candidate, TYRA-300, addresses a significant unmet need in muscle invasive bladder cancer, with potential for expansion into other FGFR3-driven malignancies. The SNAP platform's ability to rapidly design and optimize drug candidates provides a competitive advantage in the fast-evolving field of precision oncology. Key value drivers include the successful completion of preclinical studies for TYRA-300 and subsequent advancement into clinical trials. Upcoming milestones include IND submission for TYRA-300 and initial clinical data readouts. Potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies developing similar targeted therapies. With a market capitalization of $1.83B and a beta of 0.96, Tyra Biosciences offers investors exposure to the high-growth potential of the biotechnology sector.

Based on FMP financials and quantitative analysis

TYRA Key Highlights

• Lead product candidate TYRA-300 targets FGFR3, a validated oncology target in muscle invasive bladder cancer.
• Proprietary SNAP platform enables rapid and precise drug design, addressing drug resistance mechanisms.
• Pipeline includes programs targeting FGFR2, FGFR3, RET, and FGFR4, expanding therapeutic applications.
• Preclinical-stage company with upcoming milestones including IND submission and clinical trial initiation.
• Market capitalization of $1.83B reflects investor confidence in the company's technology and pipeline.

Who Are TYRA's Competitors?

TYRA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are TYRA's Key Strengths?

• Proprietary SNAP platform for rapid drug design.
• Strong focus on overcoming tumor resistance.
• Promising lead product candidate, TYRA-300.
• Experienced management team with expertise in drug development.

What Are TYRA's Weaknesses?

• Preclinical-stage company with no approved products.
• High reliance on the success of its lead product candidate.
• Limited financial resources compared to larger pharmaceutical companies.
• Vulnerable to clinical trial failures and regulatory hurdles.

What Could Drive TYRA Stock Higher?

• IND submission for TYRA-300 for muscle invasive bladder cancer.
• Initiation of Phase 1 clinical trial for TYRA-300.
• Advancement of FGFR2 inhibitor into preclinical development.
• Expansion of SNAP platform to additional kinase targets.

What Are the Key Risks for TYRA?

• Negative return on equity (-42.7%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for TYRA-300 or other pipeline candidates.
• Regulatory delays or rejection of drug candidates.
• Competition from established pharmaceutical companies with greater resources.
• Dependence on the success of the SNAP platform and its ability to generate viable drug candidates.
• Reliance on key personnel and the ability to attract and retain talent.

What Are the Growth Opportunities for TYRA?

• Expansion into Additional FGFR3-Driven Malignancies: Tyra Biosciences has the opportunity to expand the application of TYRA-300 beyond muscle invasive bladder cancer to other FGFR3-driven malignancies, such as upper tract urothelial carcinoma and certain hematological cancers. The market for FGFR3-targeted therapies in these indications is estimated to reach several billion dollars, offering significant growth potential. This expansion strategy leverages the existing preclinical data and clinical development expertise for TYRA-300, accelerating the development timeline and reducing risk.
• Advancement of FGFR2 Inhibitor for Intrahepatic Cholangiocarcinoma (iCCA): Tyra Biosciences is developing a selective FGFR2 inhibitor for the treatment of iCCA, a rare and aggressive cancer with limited treatment options. The market for iCCA therapies is projected to grow significantly in the coming years, driven by increasing incidence and improved diagnosis. Successful development and commercialization of the FGFR2 inhibitor would establish Tyra Biosciences as a leader in the iCCA treatment landscape and generate substantial revenue.
• Development of RET Inhibitor for RET-Altered Cancers: Tyra Biosciences is pursuing a program targeting rearranged during transfection (RET) kinase for the treatment of RET-altered cancers, including non-small cell lung cancer and thyroid cancer. RET alterations are present in a subset of these cancers, making them amenable to targeted therapy. The market for RET inhibitors is rapidly expanding, with several approved therapies demonstrating significant clinical benefit. Tyra Biosciences aims to develop a best-in-class RET inhibitor with improved selectivity and efficacy.
• Application of SNAP Platform to Additional Kinase Targets: The SNAP platform has the potential to be applied to a wide range of kinase targets beyond FGFRs and RET, expanding Tyra Biosciences' pipeline and therapeutic reach. By leveraging the platform's ability to rapidly design and optimize drug candidates, Tyra Biosciences can efficiently identify and develop novel therapies for various diseases. This platform-driven approach provides a sustainable competitive advantage and enables the company to address unmet needs in multiple therapeutic areas.
• Strategic Partnerships and Collaborations: Tyra Biosciences can accelerate its growth through strategic partnerships and collaborations with pharmaceutical companies, academic institutions, and other biotech firms. These partnerships can provide access to additional resources, expertise, and technologies, enabling Tyra Biosciences to expand its pipeline, accelerate clinical development, and commercialize its products more effectively. Potential partnership opportunities include co-development agreements, licensing deals, and joint ventures.

What Opportunities Does TYRA Have?

• Expansion into additional FGFR3-driven malignancies.
• Advancement of FGFR2 inhibitor for intrahepatic cholangiocarcinoma.
• Development of RET inhibitor for RET-altered cancers.
• Strategic partnerships and collaborations with pharmaceutical companies.

What Threats Does TYRA Face?

• Competition from established pharmaceutical companies.
• Clinical trial failures and regulatory setbacks.
• Changes in the regulatory landscape.
• Economic downturns and market volatility.

What Are TYRA's Competitive Advantages?

• Proprietary SNAP platform enables rapid and precise drug design.
• Strong intellectual property portfolio protecting its drug candidates and technologies.
• Expertise in kinase inhibitor development and precision oncology.
• Focus on overcoming tumor resistance, a major challenge in cancer treatment.

What Does TYRA Do?

Tyra Biosciences, Inc., founded in 2018 and based in Carlsbad, California, is a biopharmaceutical company focused on developing innovative therapies to combat tumor resistance and improve outcomes for cancer patients. Recognizing the limitations of existing cancer treatments due to acquired resistance, Tyra Biosciences has developed the SNAP platform, a proprietary technology that enables the rapid and precise design of drug candidates. This platform facilitates iterative molecular snapshots, allowing for the creation of highly selective inhibitors targeting specific mutations and resistance mechanisms. The company's lead product candidate, TYRA-300, is a selective inhibitor of fibroblast growth factor receptor 3 (FGFR3), currently in preclinical development for the treatment of muscle invasive bladder cancer (MIBC). FGFR3 alterations are implicated in a significant portion of MIBC cases, making it a promising therapeutic target. Beyond TYRA-300, Tyra Biosciences is advancing programs targeting FGFR2 in intrahepatic cholangiocarcinoma (iCCA), FGFR3-related achondroplasia, rearranged during transfection (RET) kinase, and FGFR4-related cancers. These programs reflect the company's broader strategy of addressing unmet needs in oncology and genetic diseases through precision medicine approaches. Tyra Biosciences aims to transform cancer treatment by developing therapies that not only target the initial tumor but also overcome resistance mechanisms, ultimately leading to more durable responses and improved patient outcomes.

What Products and Services Does TYRA Offer?

• Develops therapies to overcome tumor resistance in cancer patients.
• Utilizes the SNAP platform for rapid structural design of drug candidates.
• Focuses on selective inhibitors of fibroblast growth factor receptors (FGFRs).
• Targets FGFR3 for the treatment of muscle invasive bladder cancer.
• Develops programs targeting FGFR2, FGFR3, RET, and FGFR4.
• Aims to improve outcomes for patients with cancer through precision medicine.

How Does TYRA Make Money?

• Develops and patents novel drug candidates targeting specific cancer-related pathways.
• Out-licenses or co-develops drug candidates with larger pharmaceutical companies.
• Generates revenue through milestone payments, royalties, and commercial sales of approved therapies.

What Industry Does TYRA Operate In?

The biotechnology industry is characterized by rapid innovation, high risk, and significant potential for reward. Precision oncology, the focus of Tyra Biosciences, is a rapidly growing segment driven by advances in genomics and targeted therapies. The competitive landscape includes established pharmaceutical companies and emerging biotech firms developing kinase inhibitors and other targeted cancer treatments. Tyra Biosciences differentiates itself through its SNAP platform, which enables the rapid design and optimization of drug candidates to overcome resistance mechanisms. The market for targeted cancer therapies is expected to continue to grow, driven by the increasing prevalence of cancer and the demand for more effective and personalized treatments.

Who Are TYRA's Key Customers?

• Patients with cancer who are seeking more effective and targeted treatments.
• Oncologists and other healthcare professionals who treat cancer patients.
• Pharmaceutical companies that are looking to expand their oncology portfolios.

Company Profile

Tyra Biosciences, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Carlsbad, US. The company is led by CEO Todd Harris. TYRA has traded publicly since 2021.

F-Score 1/9Financial Health

Tyra Biosciences, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 43.31 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE -43%Key Financial Metrics

Return on equity for Tyra Biosciences, Inc. stands at -42.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -31.8%, showing how much profit it generates from its asset base. Its free cash flow yield is -5.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 20.49 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.9%, the inverse of the P/E and a quick read on earnings relative to price.

TYRA Valuation & Market Position

With a $1.83B market cap, Tyra Biosciences, Inc. sits in the small-cap segment of the market. Relative to its peer group, TYRA's quantitative score of 59/100 is below the peer average of 71/100.

FY2026 estForward Outlook

Wall Street analysts project Tyra Biosciences, Inc. revenue of about $687K for fiscal 2026, with EPS near $-2.59. The estimate reflects 7 contributing analysts.

TYRA Financials

TYRA Latest News

TYRA Analyst Consensus

TYRA MoonshotScore

Latest Tyra Biosciences, Inc. Analysis

Common Questions About TYRA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources